ClinicalTrials.gg
RecruitingNCT06168019ICOPEUpdated Nov 28, 2025

Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

An observational study in Influenza, COVID-19 and SARS-COV-2 Infection, sponsored by Boston University. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boston University · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Planned enrollment
14th of 122
10,000 · median 261
Started
2023
with 41 others
Observational
122 of 966
14 open now
Primary completion
2028-06
later than 68 of 83 live
Registered
875th of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 14th largest by planned enrollment of the 122 observational ones that give a count, is one of 42 that started in 2023, is one of 122 observational ones, reaches primary completion later than 68 of the 83 other live ones, and was the 875th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 50 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.

Read the detailed description

All pregnant women enrolled in the study will receive standard of care throughout their pregnancy, labor and delivery and post-partum to discharge. Wherever possible, study visits will coincide with regular antenatal (ANC) care and blood draws will be added to standard blood draws during ANC, labor and delivery and postpartum care. Women will be counselled about procedure to reduce the risk of acquiring ORV during pregnancy. Since this study is observational, we do not anticipate any specific safety concerns with study interviews and procedures, but the investigators will monitor potential adverse events to determine if they are likely or possibly study related.

PRIMARY OBJECTIVE: Determine the prevalence, incidence, and maximal severity of symptomatic or asymptomatic COVID-19 in pregnant women to day 42 postpartum/after miscarriage on maternal outcomes. Secondary analysis will evaluate whether influenza/Other Respiratory Viruses (ORV) infection or COVID-19 vaccination modifies or mediates this risk.

SECONDARY OBJECTIVE: Determine the effect of maternal COVID-19 infection on the fetus and/or neonate during pregnancy through day 7 of life. Secondary analysis will focus on whether influenza/ORV or vaccination modifies, and pre-term birth mediates this risk.

EXPLORATORY OBJECTIVE: Characterize patterns and trajectories of host response/ inflammatory biomarkers as potential mediators of COVID-19 ± Influenza and ORV infection on progression to severe illness in pregnant women/mothers admitted to Government Medical College hospital with COVID-19. Modifiers include COVID-19 , Influenza and other ORV vaccinations.

03

Conditions studied

  • Influenza
  • COVID-19
  • SARS-COV-2 Infection
  • Other Respiratory Viruses
  • Perinatal Morbidity
  • Infant Morbidity

Keywords

  • Pregnant women
  • Government Medical College Hospital, Nagpur, India
  • Covid-19 vaccination
  • Antenatal care
  • Postpartum
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

The study population is pregnant women in their first trimester of pregnancy who present to the outpatient antenatal care clinic at Government Medical College Hospital in Nagpur, India. Women will be aged 18-50 and can be from any race or ethnic group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Women aged 18 to 50 years registering for antenatal care (ANC) at Government Medical College Hospital (GMC) Nagpur, India

  • Estimated Gestational Age at registration \<14 weeks based on ultrasound report at the baseline study visit;
  • Intends to receive pregnancy, labor and delivery and neonatal care at GMC;
  • Plans to live within the city limits of Nagpur throughout their pregnancy and labor and delivery to facilitate access to GMC for evaluation of ILI and COVID-19 symptoms;
  • Willing to be contacted two times per week by call or text for ILI/ COVID-19 symptom screening and return to GMC for evaluation and an NP swab/evaluation if symptoms are reported;
  • Willing to take temperature with the provided digital thermometer, and maintain a symptom diary after training;
  • Willing to provide information on pregnancy and neonatal outcomes if care occurs outside GMC;
  • Willing to permit venous blood draws on at least 4 timepoints --1) Baseline study visit, 2)28-34 weeks, 3) 37 weeks - prior to delivery and 4) after delivery;
  • Willing to permit blood draws if hospitalized at GMC for COVID-19 infection;
  • Willing to consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Anyone who is deemed to have limited decision-making capacity as defined by Boston University IRB i.e. Substantial impairment of cognitive functions (e.g. attention, comprehension, memory, and intellect), or conditions that might affect their cognitive functions.
  • Anyone who is deemed to have limited capacity to consent as defined by Boston University Institutional Review Board (IRB) i.e. The ability to provide legally effective consent to enroll in a research study (AAHRPP definition).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE)

    Pregnant women in their first trimester of pregnancy who present to the outpatient antenatal care clinic at Government Medical College Hospital in Nagpur, India.

    Other: Exposures

Interventions

  • OtherExposures

    COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn

06

What researchers measure

Primary outcomes

  1. Maternal composite adverse outcome variable

    The maternal composite variable includes any of following 3 outcomes: * Preterm labour, defined as hospitalization for the management of onset of labor before fetus age 37 weeks, regardless of when birth occurs; * Pre-eclampsia with severe features, defined as the new onset of systolic blood pressure \>160 mm Hg and/or diastolic blood pressure \>110 mm Hg and proteinuria (World Health Organization (WHO) definition); * Mortality at any time between enrolment and day 42 post-partum/after miscarriage.

    Time frame: 1 year

Secondary outcomes

  1. Perinatal composite adverse outcome variable

    The perinatal adverse outcomes includes any of the following 3 outcomes: * Preterm birth, defined as gestational age of \<37 weeks at birth, based on gestational age dating by ultrasound obtained before study enrolment; * Neonatal critical illness, defined as any sign of critical illness in the newborn and/or continued hospitalization after day 7 of life; * Perinatal Mortality, defined as fetal mortality after week 20 of pregnancy through neonatal death by day 7 of life

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Boston University School of Public Health, Global Health
    Boston, Massachusetts 02118, United States
    Recruiting
  • Government. Medical College Hospital
    Nagpur, India
    Recruiting
    • Archana Patel, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2028, 54 months after the start.

Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 54 months is above that.

Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 13, 2023
StartActual
Dec 26, 2023
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06168019
Lead sponsor
Boston University
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Dec 26, 2023
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 28, 2025

Study contacts

Patricia Hibberd, MD PhD
Contact
plh0@bu.edu
617-358-2046
Aboli Goghari, MPH
Contact
agoghari@bu.edu
617-358-2310
Patricia Hibberd, MD PhD
principal investigator · Boston University School of Public Health, Global Health
Archana Patel, MD
principal investigator · Lata Medical Research Foundation, Nagpur India

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion